TGFB1 and neoplasm: Thus, while the primary objective for our in vivo study was to determine how blockade of TGF-β signaling might alter tumor progression at a relatively early stage utilizing the novel TGF-β inhibitor RER, a question for our future research is how RER compares with other TGF-β inhibitors in blocking tumor progression.